Introduction {#section5-1470320320934716}
============

Obstructive sleep apnoea (OSA) has an estimated prevalence of 2% in women and 4% in men.^[@bibr1-1470320320934716]^ OSA is characterised by repetitive bouts of upper-airway collapse during sleep, resulting in intermittent periods of hypoxia and hypercapnia, fragmented sleep and heightened sympathetic nervous system activity.^[@bibr2-1470320320934716]^ Patients with OSA have an increased incidence of various diseases, including insulin resistance, hypertension, stroke, acute myocardial infarct, arrhythmia and cerebrovascular ischaemic complications.^[@bibr3-1470320320934716][@bibr4-1470320320934716][@bibr5-1470320320934716]--[@bibr6-1470320320934716]^

Previous studies have indicated that OSA is a complex disorder affected by a combination of genetic, environmental and developmental factors that interact to determine the overall phenotype.^[@bibr7-1470320320934716]^ Despite extensive research in this field, the aetiology of most OSA remains unclear, and genetic polymorphisms have been proposed as susceptibility factors in patients with OSA.^[@bibr8-1470320320934716][@bibr9-1470320320934716][@bibr10-1470320320934716]--[@bibr11-1470320320934716]^

During the past decade, the role of the renin--angiotensin system (RAS) in the development of OSA has generated interest. Angiotensin-converting enzyme (ACE) -- the key enzyme in the RAS -- is released from the cell membrane.^[@bibr12-1470320320934716]^ ACE is a zinc metallopeptidase that converts angiotensin I to angiotensin II.^[@bibr13-1470320320934716]^

The angiotensin-converting enzyme (*ACE*) gene consists of either an insertion (I) allele or a deletion (D) allele, forming three possible genotypes: II, ID and DD.^[@bibr14-1470320320934716],[@bibr15-1470320320934716]^ The *ACE* gene locus is the major locus that determines serum and tissue concentrations of ACE.^[@bibr16-1470320320934716],[@bibr17-1470320320934716]^ Several studies have shown that the *ACE* I/D polymorphism is a possible risk factor for myocardial infarction,^[@bibr18-1470320320934716]^ overweight/obesity,^[@bibr19-1470320320934716]^ hypertrophic cardiomyopathies^[@bibr20-1470320320934716]^ and hypertension.^[@bibr21-1470320320934716]^

The hypothesis that *ACE* I/D polymorphisms may play important roles in the risk of OSA in Chinese has also been debated. Many studies have investigated the potential relationship between *ACE* I/D gene polymorphisms and OSA, but the results have been inconsistent. Some meta-analyses have reported a correlation between *ACE* I/D gene polymorphisms and OSA, although the results were negative or the subjects were not Chinese.^[@bibr22-1470320320934716][@bibr23-1470320320934716][@bibr24-1470320320934716]--[@bibr25-1470320320934716]^

The *ACE* I/D polymorphism has been associated with other disorders in the Chinese population.^[@bibr26-1470320320934716],[@bibr27-1470320320934716]^ Therefore, this association should be investigated in Chinese patients and more comparisons should be performed.

To evaluate the association between the *ACE* I/D polymorphism and the risk of OSA in the Chinese population further, we conducted a meta-analysis by combining genotype data from all eligible studies published to date.

Methods {#section6-1470320320934716}
=======

Publication search {#section7-1470320320934716}
------------------

We searched relevant studies from PubMed, Embase, Cochrane Library, the Chinese National Knowledge Infrastructure (CNKI) database, the Wan Fang database and the Weipu database. The search strategy to identify all possible studies involved the use of the following keywords in the abstract: 'OSAHS', 'OSAS', 'OSA', 'obstructive sleep apnoea syndrome', 'obstructive sleep apnoea hypopnoea syndrome', 'obstructive sleep apnoea', 'angiotensin converting enzyme' and 'ACE'. The reference lists of retrieved reviews and articles were searched by hand. If more than one article was published using the same case series, only the study with largest sample size was included. The literature search was updated on 30 July 2019.

Inclusion criteria {#section8-1470320320934716}
------------------

The included studies had to meet the following criteria: (a) evaluated *ACE* mutation status and relationship to OSA in Chinese children or adults; (b) were full-text articles; (c) were case-control studies; (d) had sufficient published data to estimate an odds ratio (OR) and 95% confidence interval (CI); (e) included at least two comparison groups (OSA group vs. control group); (f) mentioned hypertension in the OSA group; and (g) were observational studies published in Chinese or English.

Data extraction and quality evaluation {#section9-1470320320934716}
--------------------------------------

Two authors independently reviewed the titles, abstracts and full text to assess the articles for compliance with the inclusion criteria. Disagreement was followed by discussion until consensus was reached. Information was carefully extracted from all eligible publications independently by two of the authors according to the inclusion criteria listed above. The following information was extracted from each study: (a) name of the first author; (b) year of publication; (c) sample size of cases and controls; (d) genotype distributions of cases and controls; (e) presence or absence of hypertension; and (f) results of Hardy--Weinberg equilibrium (HWE) test in controls. The quality of the included literature was evaluated using the Newcastle--Ottawa Scale (NOS). According to the NOS evaluation criteria, each included study scored ⩾6 stars, indicating that it was of high quality.

Statistical methods {#section10-1470320320934716}
-------------------

We assessed HWE in the controls for each study using a goodness-of-fit test (chi-square or Fisher's exact test), and a *p*-value of \<0.05 was considered to indicate significant disequilibrium. ORs with 95% CI were used to assess the strength of association between the *ACE* I/D gene polymorphism and OSA risk. The pooled ORs were performed for the following comparisons: D versus I, DD versus II, ID versus II; DD+ID versus II; DD versus ID+II and ID versus DD+II. Assumption of heterogeneity was checked by the chi-square-based *Q*-test. A *p*-value of \>0.1 for the *Q*-test indicates a lack of heterogeneity among studies. So, the pooled OR estimate of each study was calculated by the fixed-effects model (the Mantel--Haenszel method).^[@bibr18-1470320320934716]^ Otherwise, the random-effects model (DerSimonian and Laird method) was used.^[@bibr19-1470320320934716]^

Subgroup analyses were performed for hypertension. The diagnostic standard used for hypertension was according to 2010 Chinese guidelines for the prevention and treatment of hypertension: in the absence of antihypertensive drugs, blood pressure was measured three times on different days. Patients with hypertension were those with a systolic blood pressure ⩾140 mmHg or a diastolic blood pressure ⩾90 mmHg, or patients who were previously diagnosed with hypertension and were currently using antihypertensive drugs and whose blood pressure was \<140/90 mmHg.

An estimate of potential publication bias was carried out by assessing funnel plots, in which the standard error of log (OR) of each study was plotted against its log (OR). An asymmetric plot indicates possible publication bias. Funnel plot asymmetry was assessed with Egger's linear regression test on the natural logarithm scale of the OR. The significance of the intercept was determined by the *t*-test suggested by Egger (*p*\<0.05 was considered indicative of statistically significant publication bias).^[@bibr28-1470320320934716]^ If publication bias existed, the Duval and Tweedie non-parametric 'trim and fill' method was used to adjust for it. All statistical tests were performed using Stata v15.0 (StataCorp, College Station, TX).

Results {#section11-1470320320934716}
=======

Study characteristics {#section12-1470320320934716}
---------------------

A total of 501 articles were retrieved from PubMed (*n*=91), Embase (*n*=145), the Cochrane Library (*n*=31), CNKI (*n*=27), the Wanfang database (*n*=159) and the Weipu database (*n*=48). Of these, 191 articles published in Chinese or English were excluded because they were duplicates. In addition, 293 articles were excluded for the following reasons: they were review articles, editorials or case reports; the preliminary result was not about the *ACE* I/D gene polymorphism or outcome; they investigated the relationship of ACE inhibitor to diseases; or polymorphisms or the *ACE* I/D polymorphism did not concern OSA or include Chinese in the study population.

Seventeen investigations were reported on the association of the *ACE* I/D gene polymorphism with OSA susceptibility. However, two were published in a language other than Chinese or English, two reported animal experiments, one reported grouping in syndrome differentiation of Traditional Chinese Medicine and two did not include a control group.

Finally, 10 studies were identified to analyse the association between the *ACE* I/D gene polymorphism and OSA susceptibility in our review ([Figure 1](#fig1-1470320320934716){ref-type="fig"}).^[@bibr29-1470320320934716][@bibr30-1470320320934716][@bibr31-1470320320934716][@bibr32-1470320320934716][@bibr33-1470320320934716][@bibr34-1470320320934716][@bibr35-1470320320934716][@bibr36-1470320320934716][@bibr37-1470320320934716]--[@bibr38-1470320320934716]^ One of the investigations was performed in children. Study characteristics are summarised in [Table 1](#table1-1470320320934716){ref-type="table"}. Genotype distributions in the control groups of the included studies were in agreement with HWE, except for three studies ([Table 1](#table1-1470320320934716){ref-type="table"}). The quality of the studies was assessed using the NOS quality assessment scale; quality scores ranged from 6 to 8 (mean 6.8; [Table 1](#table1-1470320320934716){ref-type="table"}).

![Flow chart of study selection.](10.1177_1470320320934716-fig1){#fig1-1470320320934716}

###### 

Main characteristics of all studies included in the meta-analysis.

![](10.1177_1470320320934716-table1)

  First author (year)   Language   Case   Control   Sample size   With hypertension   HWE   NOS                                             
  --------------------- ---------- ------ --------- ------------- ------------------- ----- ----- ---- ---- ---- ----- --------- ---- ----- ---
  Xiao (1998)           Chinese    0      28        22            28                  72    8     26   16   42   58    50/50     30   Yes   6
  Zhang (2000)          English    11     20        30            42                  80    18    31   19   67   69    61/68     61   Yes   8
  Ping (2001)           Chinese    8      30        42            46                  114   15    30   15   60   60    80/60     41   Yes   7
  Li S (2004)           Chinese    13     71        8             97                  87    16    34   0    66   34    92/50     0    No    6
  Li (2004)             Chinese    21     12        27            54                  66    19    3    8    41   19    60/30     30   No    7
  Zhang (2004)          Chinese    36     46        39            118                 124   19    40   41   78   122   121/100   0    Yes   7
  Gu (2006)             Chinese    60     42        22            162                 86    30    38   56   98   140   124/124   0    No    8
  Tong (2011)           Chinese    32     13        6             77                  25    11    36   13   58   62    51/60     51   Yes   6
  Huang (2016)          Chinese    25     55        77            105                 209   27    40   25   94   90    92/157    85   Yes   7
  Huang (2017)          Chinese    12     46        54            70                  154   16    30   14   62   58    112/60    60   Yes   6

D: deletion; I: insertion; HWE: Hardy--Weinberg equilibrium; NOS: Newcastle--Ottawa Scale for quality assessment of study.

Meta-analysis results {#section13-1470320320934716}
---------------------

In the meta-analysis of 10 studies, we found obvious between-study heterogeneity in the six comparison models. Thus, the random-effects model was used to calculate pooled ORs with corresponding 95% CIs. The overall result showed that there was no statistically significant association between the *ACE* gene polymorphism and OSA: D versus I, OR=0.770, 95% CI 0.461--1.287, *p*=0.319; DD versus II, OR=0.538, 95% CI 0.204--1.419, *p*=0.211; DD versus DI+II, OR=0.720, 95% CI 0.342--1.516, *p*=0.388; ID versus DD+II, OR=0.804, 95% CI 0.585--1.106, *p*=0.181; DD+ID versus II, OR=0.664, 95% CI 0.351--1.257, *p*=0.209; ID versus II, OR=0.695, 95% CI 0.420--1.149, *p*=0.156 ([Table 2](#table2-1470320320934716){ref-type="table"}).

###### 

Meta-analysis of the association between the ACE I/D polymorphism and OSA.

![](10.1177_1470320320934716-table2)

  Genetic contrasts   Design   No. of studies         Test of association    Test of heterogeneity                   
  ------------------- -------- ---------------------- ---------------------- ----------------------- ------- ------- -------
  D vs. I             All      10                     0.770 (0.461--1.287)   1.00                    0.319   91.6    0.000
  All in HT           14       0.611 (0.397--0.939)   2.24                   0.025                   88.4    0.000   
  OSA with HT         7        0.517 (0.277--0.966)   2.07                   0.039                   88.0    0.000   
  OSA WO HT           7        0.720 (0.399--1.299)   1.09                   0.275                   88.2    0.000   
  DD vs. II           All      10                     0.538 (0.204--1.419)   1.25                    0.211   89.3    0.000
  All in HT           14       0.364 (0.160--0.827)   2.41                   0.016                   85.1    0.000   
  OSA with HT         7        0.299 (0.104--0.864)   2.23                   0.026                   80.8    0.000   
  OSA WO HT           7        0.444 (0.130--1.515)   1.30                   0.195                   86.5    0.000   
  DD vs. (DI+II)      All      10                     0.720 (0.342--1.516)   0.86                    0.388   88.0    0.000
  All in HT           14       0.518 (0.270--0.994)   1.98                   0.048                   83.6    0.000   
  OSA with HT         7        0.441 (0.143--1.362)   1.42                   0.155                   86.8    0.000   
  OSA WO HT           7        0.593 (0.264--1.330)   1.27                   0.205                   81.0    0.000   
  ID vs. (DD+II)      All      10                     0.804 (0.585--1.106)   1.34                    0.181   53.5    0.022
  All in HT           14       0.787 (0.642--0.963)   2.32                   0.020                   40.5    0.058   
  OSA with HT         7        0.602 (0.449--0.808)   3.38                   0.001                   36.1    0.153   
  OSA WO HT           7        1.007 (0.759--1.334)   0.05                   0.964                   9.10    0.359   
  DD+ID vs. II        All      10                     0.664 (0.351--1.257)   1.26                    0.209   85.6    0.000
  All in HT           14       0.524 (0.313--0.877)   2.46                   0.014                   79.9    0.000   
  OSA with HT         7        0.407 (0.253--0.654)   3.71                   0.00                    55.0    0.038   
  OSA WO HT           7        0.657 (0.275--1.568)   0.95                   0.344                   84.5    0.000   
  ID vs. II           All      10                     0.695 (0.420--1.149)   1.42                    0.156   70.9    0.000
  All in HT           14       0.603 (0.401--0.906)   2.43                   0.015                   59.9    0.002   
  OSA with HT         7        0.448 (0.319--0.631)   4.61                   0.505                   0.00    0.755   
  OSA WO HT           7        0.778 (0.373--1.626)   0.67                   0.75                    72.8    0.001   

ACE: angiotensin-converting enzyme; OSA: obstructive sleep apnoea; OR: odds ratio; CI: confidence interval; HT: hypertension.

Subgroup analysis {#section14-1470320320934716}
-----------------

In the subgroup analysis of patients with and without hypertension, significant associations were found in patients with hypertension: D versus I, OR=0.517, 95% CI 0.277--0.966, *p*=0.039; DD versus II, OR=0.299, 95% CI 0.104--0.864, *p*=0.026; DD versus (DI+II), OR=0.441, 95% CI 0.143--1.362, *p*=0.155; ID versus DD+II, OR=0.602, 95% CI 0.449--0.808, *p*=0.001; DD+ID versus II, OR=0.407, 95% CI 0.253--0.654, *p*=0.000 ([Table 2](#table2-1470320320934716){ref-type="table"}).

Sensitivity analysis {#section15-1470320320934716}
--------------------

Sensitivity analysis was carried out to identify potentially influential studies by sequential omission of each individual study. We found statistically similar results after sequentially excluding each study, suggesting high stability of the meta-analysis results.

Publication bias {#section16-1470320320934716}
----------------

To investigate publication bias, Egger's linear regression was performed for the association between *ACE* I/D polymorphisms and OSA. We did not detect publication bias of the meta-analysis for the association between the *ACE* I/D gene polymorphism and OSA risk (*p*\>0.05). There was no obvious asymmetry in the shape of the funnel plots.

Discussion {#section17-1470320320934716}
==========

OSA is a complex disease caused by multiple genetic and other factors.^[@bibr39-1470320320934716]^ Recently, epidemiological studies have evaluated the association between the *ACE* I/D polymorphism and OSA risk, but the results remain inconclusive. Barcelo et al.^[@bibr40-1470320320934716]^ reported that *ACE* I/D polymorphisms were not associated with increased susceptibility to OSA, whereas Chmielewska^[@bibr41-1470320320934716]^ suggested that the *ACE* I/D polymorphism was associated with OSA. Therefore, we performed this meta-analysis to investigate whether an association exists between potential polymorphisms of the *ACE* I/D gene and OSA risk.

The present meta-analysis comprised 10 studies, including 843 cases and 759 controls. Only one study was in children, and our study covered a wide range of the Chinese population. The strength of our meta-analysis is based on the high number of published studies, which allowed us to achieve sufficient statistical power to detect a modest effect estimate. The results indicated that the *ACE* I/D polymorphism was not associated with elevated OSA risk in the overall study population. This finding was consistent with those from previous meta-analyses, which indicated no association among the Chinese population.^[@bibr22-1470320320934716],[@bibr24-1470320320934716],[@bibr42-1470320320934716]^ Considering the association of OSA and hypertension, we conducted a subgroup analysis in patients based on the presence or absence of hypertension. The significant association between this polymorphism and OSA risk in some genotypes in hypertensive patients was consistent with a previous report, but that study included Caucasians and Asians.^[@bibr24-1470320320934716]^ Lin reported that the *ACE* I/D polymorphism may be a risk factor for OSA with hypertension in Asians, but only four studies were included.^[@bibr25-1470320320934716]^ Our results also differ from research by Lee et al., which reported no association between this polymorphism and OSA with hypertension.^[@bibr22-1470320320934716]^ To our knowledge, the previous research differed from our current research because our study targeted only the Chinese population, and subgroup analysis was performed in patients with hypertension.

Heterogeneity is an important issue when performing meta-analyses. Between-study heterogeneity existed in overall comparisons. In the hypertension subgroup analysis, we found that heterogeneity was decreased in the subgroup, suggesting that certain effects of genetic variants are specific to hypertension.

In addition, we obtained statistically similar results in the sensitivity analysis, which sequentially excluded individual studies. Further, we assessed publication bias by using Egger's test in the present study. These analyses indicated the stability and reliability of the meta-analysis results in our study.

Some limitations of this meta-analysis should be acknowledged. First, the heterogeneity and small sample size may have distorted the meta-analysis, although some of the heterogeneity was resolved in the hypertension subgroup analysis. Second, our results were based on unadjusted effect estimates and confidence intervals, and confounding factors were not controlled. Third, the subgroup results should be interpreted with caution because of the limited statistical power. We could not examine the association of *ACE* I/D polymorphism and OSA activity or clinical features due to the limited amount of data. Despite these limitations, our meta-analysis had some advantages. First, a substantial number of cases and controls were pooled from different studies, which significantly increased the statistical power of the analysis. Second, the results of the subgroup and sensitivity analyses were not materially altered and did not result in different conclusions, indicating that our results were robust. Third, Egger's test did not detect any publication bias, indicating that our results were unbiased.

In conclusion, this meta-analysis of 10 studies strongly suggested that the *ACE* I/D polymorphism is not associated with increased risk of OSA in a Chinese population. Subgroup analysis revealed a significant correlation in the hypertension subpopulation. Accordingly, our findings indicate that the *ACE* I/D polymorphism plays a role in the pathogenesis of OSA with hypertension in a Chinese population. However, *ACE* I/D gene polymorphisms are not the only cause of OSA, and further studies are essential to elucidate the potential relationship between other genes and OSA.
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